Results 1 to 10 of about 89,290 (238)

Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections

Antimicrobial Agents and Chemotherapy, 2020
The comparative efficacy of ceftazidime-avibactam and meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections remains unknown.
Christopher Polk, Danya Roshdy
exaly   +2 more sources

Insights into the Thermal Degradation Kinetics of β-Lactam Antibiotics: A Comparative Study of Cefazolin, Ceftriaxone, and Meropenem [PDF]

Antibiotics
Background/Objectives: The thermal stability and degradation kinetics of β-lactam antibiotics are critical for understanding their behavior under processing and storage conditions.
Ovidiu Ghirlea, Amalia Ridichie, Mirela Voicu, Adriana Ledeți, Ioan Bîtcan, Laura Sbârcea, Diana Dreavă, Ionuț Ledeți, Cristina Trandafirescu, Marius Murariu   +9 more
doaj   +2 more sources

Comparison of Intravenous Microdialysis and Standard Plasma Sampling for Monitoring of Vancomycin and Meropenem Plasma Concentrations—An Experimental Porcine Study

Antibiotics, 2023
Microdialysis is a catheter-based method suitable for dynamic sampling of unbound antibiotic concentrations. Intravenous antibiotic concentration sampling by microdialysis has several advantages and may be a superior alternative to standard plasma ...
Johanne Gade Lilleøre, Sofus Vittrup, Sara Kousgaard Tøstesen, Pelle Hanberg, Maiken Stilling, Mats Bue   +5 more
doaj   +1 more source

Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2023
Importance Meropenem is a widely prescribed β-lactam antibiotic. Meropenem exhibits maximum pharmacodynamic efficacy when given by continuous infusion to deliver constant drug levels above the minimal inhibitory concentration.
G. Monti, N. Bradic, Matteo Marzaroli, A. Konkayev, E. Fominskiy, Y. Kotani, V. Likhvantsev, E. Momesso, P. Nogtev, R. Lobreglio, I. Redkin, F. Toffoletto, Andrea Bruni, M. Baiardo Redaelli, N. D’Andrea, G. Paternoster, A. Scandroglio, Francesca Gallicchio, Mariano Ballestra, M. Calabró, A. Cotoia, Romina Perone, Raffaele Cuffaro, G. Montrucchio, V. Pota, S. Ananiadou, R. Lembo, M. Musu, Simon Rauch, Carola Galbiati, F. Pinelli, L. Pasin, F. Guarracino, G. Santarpino, F. Agrò, T. Bove, F. Corradi, F. Forfori, F. Longhini, Maurizio Cecconi, G. Landoni, R. Bellomo, A. Zangrillo   +42 more
semanticscholar   +1 more source

Biapenem Activity Against Meropenem-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa

Антибиотики и Химиотерапия, 2022
Currently, the diversity of resistant strains with a certain set of resistance mechanisms is growing, and the frequency of their distribution is increasing.
E. M. Gordina, S. A. Bozhkova, V. V. Shabanova   +2 more
doaj   +1 more source

Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018-2022).

Diagnostic microbiology and infectious disease, 2023
A total of 35,360 Enterobacterales isolates were consecutively collected from 75 US medical centers in 2018-2022. Among these isolates, 2612 (7.4%) were categorized as multidrug-resistant (MDR).
H. Sader, R. Mendes, Leonard R. Duncan, J. Kimbrough, C. Carvalhaes, M. Castanheira   +5 more
semanticscholar   +1 more source

In Vitro Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined β-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014–2019

Microbial Drug Resistance, 2023
We examined the in vitro susceptibility of meropenem-nonsusceptible Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii complex isolates from five consecutive annual SIDERO-WT surveillance studies (2014–2019) to cefiderocol and ...
M. Wise, J. Karlowsky, M. Hackel, M. Takemura, Y. Yamano, R. Echols, D. Sahm   +6 more
semanticscholar   +1 more source

Fast and Sensitive Method for Simultaneous Quantification of Meropenem and Vaborbactam in Human Plasma Microsamples by Liquid Chromatography–Tandem Mass Spectrometry for Therapeutic Drug Monitoring

Antibiotics, 2023
Meropenem (MRP)-Vaborbactam (VBR) is a novel beta-lactam/beta-lactamase inhibitor used for the management of difficult-to-treat Gram-negative infections.
Rossella Barone, Matteo Conti, Beatrice Giorgi, Milo Gatti, Pier Giorgio Cojutti, Pierluigi Viale, Federico Pea   +6 more
doaj   +1 more source

Preparation, Physicochemical Characterization, Antimicrobial Effects, Biocompatibility and Cytotoxicity of Co-Loaded Meropenem and Vancomycin in Mesoporous Silica Nanoparticles

Biomedicines, 2023
Mesoporous silica nanoparticles (MSNPs) have been reported as an effective system to co-deliver a variety of different agents to enhance efficiency and improve biocompatibility.
Mina Yekani, Robab Azargun, Simin Sharifi, Javid Sadri Nahand, Alka Hasani, Hadi Ghanbari, Zahra Sadat Seyyedi, Mohammad Yousef Memar, Solmaz Maleki Dizaj   +8 more
doaj   +1 more source

Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial

The Pediatric Infectious Disease Journal, 2023
Background: Ceftolozane/tazobactam, a cephalosporin-β-lactamase inhibitor combination, active against multidrug-resistant Gram-negative pathogens, is approved for treatment of adults with complicated urinary tract infections (cUTI).
E. Roilides, N. Ashouri, John S. Bradley, Matthew G. Johnson, Julia D. Lonchar, Feng-Hsiu Su, Jennifer A. Huntington, M. Popejoy, M. Bensaci, Carisa De Anda, Elizabeth G. Rhee, C. Bruno   +11 more
semanticscholar   +1 more source